NCT06385483 2026-03-19Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)National Cancer Institute (NCI)Phase 2 Active not recruiting19 enrolled 10 charts